Related Experiment Video
Updated: Aug 16, 2026

Lung CT Segmentation to Identify Consolidations and Ground Glass Areas for Quantitative Assesment of SARS-CoV Pneumonia
Published on: December 19, 2020
Integrating Quantitative CT Biomarkers to Enhance COPD Detection in the HANSE Lung Cancer Screening Program
Mustafa Abdo1, Hendrik Pott2, Martin Reck3
1LungenClinic Großhansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Großhansdorf, Germany; Internal Medicine Department I, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Background:
Lung cancer screening offers an opportunity to enhance COPD detection among adults exposed to tobacco smoke, yet guidance on CT-based referral for spirometry is limited.
Research Question:
Which low-dose CT emphysema threshold best identifies previously undiagnosed COPD in lung cancer screening subjects, and does the addition of quantitative airway biomarkers enhance detection?
Study Design And Methods:
In adults undergoing lung cancer screening, we performed spirometry to identify previously undiagnosed COPD, defined by airflow obstruction (FEV1/FVC <0.70) in current and former smokers with ≥10 pack-years. We quantified emphysema extent, airway wall thickness (Pi10), and airway branch count on low-dose CT using AI-based software and combined these measures with clinical characteristics, mainly smoking history and dyspnea, to develop an ensemble tree-based machine-learning model (Extreme Gradient Boosting) for COPD detection. A sensitivity analysis using the lower limit of normal (LLN) definition for FEV1/FVC was additionally performed.
Results:
Among 5,014 screening subjects with available spirometry, 1,115 had previously undiagnosed COPD, corresponding to a prevalence of 22.2%. In subjects without known airway disease, emphysema alone at an optimised threshold of 5.1% showed moderate performance for COPD detection (AUC 0.69 [95% CI 0.67-0.72], accuracy 66%, PPV 44%), where 41% of subjects exceeded this threshold and met criteria for confirmatory spirometry. An integrated model combining emphysema, Pi10, airway branch count, and clinical characteristics significantly improved detection (AUC 0.83 [95% CI 0.80-0.86], accuracy 78%, PPV 59%) while reducing the proportion requiring confirmatory spirometry to 34%. In a sensitivity analysis using the LLN definition of COPD, the best-performing model achieved an AUC of 0.86 (95% CI 0.83-0.89), accuracy of 84%, and PPV of 53%, while referring 22% for confirmatory spirometry.
Interpretation:
An integrated approach combining CT-derived airway biomarkers and clinical characteristics enables more efficient and targeted COPD detection within lung cancer screening programs.